Modeling Biomass Production in Seasonal Wetlands Using MODIS NDVI Land Surface Phenology

Plant primary production is a key driver of several ecosystem functions in seasonal marshes, such as water purification and secondary production by wildlife and domestic animals. Knowledge of the spatio-temporal dynamics of biomass production is therefore essential for the management of resources—particularly in seasonal wetlands with variable flooding regimes. We propose a method to estimate standing aboveground plant biomass using NDVI Land Surface Phenology (LSP) derived from MODIS, which we calibrate and validate in the Doñana National Park’s marsh vegetation. Out of the different estimators tested, the Land Surface Phenology maximum NDVI (LSP-Maximum-NDVI) correlated best with ground-truth data of biomass production at five locations from 2001–2015 used to calibrate the models (R2 = 0.65). Estimators based on a single MODIS NDVI image performed worse (R2 ≤ 0.41). The LSP-Maximum-NDVI estimator was robust to environmental variation in precipitation and hydroperiod, and to spatial variation in the productivity and composition of the plant community. The determination of plant biomass using remote-sensing techniques, adequately supported by ground-truth data, may represent a key tool for the long-term monitoring and management of seasonal marsh ecosystems.We acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI).David Aragonés, Isabel Afán, Ricardo Díaz-Delgado and Diego García Díaz (EBD-LAST) provided support for remote-sensing and LSP analyses. Alfredo Chico, José Luis del Valle and Rocío Fernández Zamudio (ESPN, ICTS-RBD) provided logistic support and taxonomic expertise during the field work (validation dataset). Ernesto García and Cristina Pérez assisted with biomass harvesting and processing (calibration dataset). Gerrit Heil provided support in the project design. This study received funding from Ministerio de Medio Ambiente-Parque Nacional de Doñana, Consejeria de Medio Ambiente, Junta de Andalucia (1999–2000): RNM118 Junta de Andalucia (2003); the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 641762 to ECOPOTENTIAL project; and the Spanish Ministry of Economy, Plan Estatal de I+D+i 2013–2016, under grant agreement CGL2016-81086-R to GRAZE project

El nuevo Justicia y la protección autonómica de los ciudadanos en Aragón [Texto impreso]

Bibliografía: p. 653-66

El nuevo Justicia y la protección autonómica de los ciudadanos en Aragón

Esta investigación pretende ser un exhaustivo estudio de una de las instituciones más novedosas dentro del sistema político español, el Justicia de Aragón. La aparición de esta institución supuso una modificación en el entramado institucional de la Comunidad Autónoma, que tuvo que adaptarse a la existencia del nuevo organismo al que se le encomendaba no sólo las funciones tradicionales de los Ombudsmen, sino que se le otorgaba la competencia para tutelar el ordenamiento jurídico aragonés y defender el Estatuto de Autonomía. El análisis tanto de su marco regulador y teórico, como de la evaluación sobre todos estos años de funcionamiento real de la institución que en la mayor parte de los casos ha desbordado lo previsto normativamente, aunque con un mayor protagonismo de ésta última, es la esencia que subyace en la naturaleza de este estudio que comienza con su inicial regulación en el Estatuto de Autonomía y comprende la labor de los tres titulares que hasta el momento han sido elegidos, y que han protagonizado tres etapas bien diferenciadas de la institución del Justiciazgo. La reacción que se ha producido en los órganos supervisados ante la labor de control y fiscalización de la actividad de la Administración Pública, y de protección de los derechos y libertades ciudadanas que desarrolla el Justicia ha sido por último otro de los factores estudiados.Hacia todas estas direcciones se ha dirigido la investigación, que aunque contiene reiteradas menciones a las figuras análogas existentes en España y al Ombudsman estatal, no es en absoluto un estudio comparado, sólo se realizan en la medida en que coadyuvan a un mayor conocimiento de la institución aragonesa

L'Europe, c' est nous : unidad didáctica. 'Nosotros somos Europa'

Unidad del área de Lengua extranjera dirigida a alumnos del primer año de Bachillerato. Propone un estudio de la Unión Europea de forma interdisciplinar, en colaboración con profesores de Geografía e Historia (situación de los paises, relaciones internacionales, etc.) y de Música (canciones, folklore, etc.). Forma parte de un proyecto educativo que pretende contribuir a la paz y solidaridad internacional, formando ciudadanos tolerantes con las diferentes culturas, solidarios y sin prejuicios. El desarrollo de la unidad ayudará a los alumnos a adquirir las capacidades siguientes: - Comprensión de producciones orales, escritas y visuales de los medios de comunicación. - Lectura autónoma y comprensión de textos y artículos de periódicos. - Utilización de las diferentes fuentes de información: mapas, gráficos, etc. - Expresión escrita (elaboración de resúmenes, cartas...). - Utilizar la lengua para expresar opiniones, desacuerdos, etc. - Respeto de otras culturas y realidades sociales diferentes. - Actitud responsable, crítica y de compromiso frente a Europa. - Tomar conciencia de la ventajas del trabajo en grupo. Está dividida en 4 dossieres: Vers la construction Européenne; L'Union Européenne au travail; Strasbourg pourquoi? y L'Europe des jeunes. Al principio de cada lección se establecen los objetivos y contenidos de la misma. Propone una evaluación inicial y formativa a lo largo de la unidad y una evaluación sumativa al final de la misma.AragónBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín 5 -3 Planta; 28014 Madrid; Tel. +34917748000; [email protected]

Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

In patients receiving anticoagulant therapy for venous thromboembolism (VTE), the important issue of anemia influence on the risk of bleeding has not been consistently studied. We used the large registry data RIETE (Registro Informatizado Enfermedad Tromboembólica) to compare the rate of major bleeding in patients receiving anticoagulant therapy for VTE according to the presence or absence of anemia at baseline. Patients with or without cancer were separately studied. Until August 2016, 63492 patients had been enrolled. Of these, 21652 (34%) had anemia and 14312 (23%) had cancer. Anemia was found in 57% of the patients with cancer and in 28% without (odds ratio 3.46; 95% CI 3.33-3.60). During the course of anticoagulant therapy, 680 patients with cancer had a major bleeding event (gastrointestinal tract 43%, intracranial 14%, hematoma 12%). Cancer patients with anemia had a higher rate of major bleeding (rate ratio [RR]: 2.52; 95% CI 2.14-2.97) and fatal bleeding (RR 2.73; 95% CI 1.95-3.86) than those without anemia. During the course of anticoagulation, 1133 patients without cancer had major bleeding (gastrointestinal tract 32%, hematoma 24%, intracranial 21%). Patients with anemia had a higher rate of major bleeding (RR 2.84; 95% CI 2.52-2.39) and fatal bleeding (RR 2.76; 95% CI 2.07-3.67) than those without. On a multivariable analysis, anemia independently predicted the risk for major bleeding in patients with and without cancer (hazard ratios: 1.66; 95% CI 1.40-1.96 and 1.95; 95% CI 1.72-2.20, respectively). During anticoagulation for VTE, both cancer- and non-cancer anemic patients had a higher risk for major bleeding than those without anemia. In anemic patients (with or without cancer), the rate of major bleeding during the course of anticoagulant therapy exceeded the rate of VTE recurrences. In patients without anemia the rate of major bleeding was lower than the rate of VTE recurrences

Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism

International audienceBackground: The choice of the imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider, patient or hospital characteristics, or over time. However, little is known about the choice of the diagnostic modalities in practice. The aim of this study was to evaluate the variations in the use of imaging modalities for patients with acute PE. Methods: Using the data from Registro Informatizado Enfermedad TromboEmbolica (RIETE), a prospective international registry of patients with venous thromboembolism (March 2001–January 2019), we explored the imaging modalities used in patients with acute PE. The imaging modalities included computed tomography pulmonary angiography, ventilation/perfusion scanning, pulmonary angiography, a combination of these tests, or PE signs and symptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging. Results: Among 38 025 patients with confirmed PE (53.1% female, age: 67.3±17 years), computed tomography pulmonary angiography was the dominant modality of diagnosis in all RIETE enrollees (78.2% [99% CI, 77.6–78.7]); including pregnant patients (58.9% [99% CI, 47.7%–69.4%]) and patients with severe renal insufficiency (62.5% [99% CI, 59.9–65.0]). A greater proportion of patients underwent ventilation/perfusion scanning in larger hospitals compared with smaller hospitals (13.1% versus 7.3%, P <0.001). The use of computed tomography pulmonary angiography varied between 13.3% and 98.3% across the countries, and its use increased over time (46.5% in 2002 to 91.7% in 2018, P <0.001). Conclusions: In a large multinational PE registry, variations were observed in the use of imaging modalities according to patient or institutional factors and over time. However, computed tomography pulmonary angiography was the dominant modality of diagnosis, even in pregnancy and severe renal insufficiency. The safety, costs, and downstream effects of these tests on PE-related and non-PE-related outcomes warrant further investigation

Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort studyResearch in context

Summary: Background: The clinical relevance of recurrent venous thromboembolism (VTE) after discontinuing anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence rates and mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19-associated VTE. Methods: A prospective, multicenter, non-interventional study was conducted between March 25, 2020, and July 26, 2023, including patients who had discontinued anticoagulation after at least 3 months of therapy. All patients from the registry were analyzed during the study period to verify inclusion criteria. Patients with superficial vein thrombosis, those who did not receive at least 3 months of anticoagulant therapy, and those who were followed for less than 15 days after discontinuing anticoagulation were excluded. Outcomes were: 1) Incidence rates of symptomatic VTE recurrences, and 2) fatal PE. The rate of VTE recurrences was defined as the number of patients with recurrent VTE divided by the patient-years at risk of recurrent VTE during the period when anticoagulation was discontinued. Findings: Among 1106 patients with COVID-19-associated VTE (age 62.3 ± 14.4 years; 62.9% male) followed-up for 12.5 months (p25-75, 6.3–20.1) after discontinuing anticoagulation, there were 38 VTE recurrences (3.5%, 95% confidence interval [CI]: 2.5–4.7%), with a rate of 3.1 per 100 patient-years (95% CI: 2.2–4.2). No patient died of recurrent PE (0%, 95% CI: 0–7.6%). Subgroup analyses showed that patients with diagnosis in 2021–2022 (vs. 2020) (Hazard ratio [HR] 2.86; 95% CI 1.45–5.68) or those with isolated deep vein thrombosis (vs. pulmonary embolism) (HR 2.31; 95% CI 1.19–4.49) had significantly higher rates of VTE recurrences. Interpretation: In patients with COVID-19-associated VTE who discontinued anticoagulation after at least 3 months of treatment, the incidence rate of recurrent VTE and the case-fatality rate was low. Therefore, it conceivable that long-term anticoagulation may not be required for many patients with COVID-19-associated VTE, although further research is needed to confirm these findings. Funding: Sanofi and Rovi, Sanofi Spain

Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort studyResearch in context

Background: The clinical relevance of recurrent venous thromboembolism (VTE) after discontinuing anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence rates and mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19-associated VTE. Methods: A prospective, multicenter, non-interventional study was conducted between March 25, 2020, and July 26, 2023, including patients who had discontinued anticoagulation after at least 3 months of therapy. All patients from the registry were analyzed during the study period to verify inclusion criteria. Patients with superficial vein thrombosis, those who did not receive at least 3 months of anticoagulant therapy, and those who were followed for less than 15 days after discontinuing anticoagulation were excluded. Outcomes were: 1) Incidence rates of symptomatic VTE recurrences, and 2) fatal PE. The rate of VTE recurrences was defined as the number of patients with recurrent VTE divided by the patient-years at risk of recurrent VTE during the period when anticoagulation was discontinued. Findings: Among 1106 patients with COVID-19-associated VTE (age 62.3 ± 14.4 years; 62.9% male) followed-up for 12.5 months (p25-75, 6.3–20.1) after discontinuing anticoagulation, there were 38 VTE recurrences (3.5%, 95% confidence interval [CI]: 2.5–4.7%), with a rate of 3.1 per 100 patient-years (95% CI: 2.2–4.2). No patient died of recurrent PE (0%, 95% CI: 0–7.6%). Subgroup analyses showed that patients with diagnosis in 2021–2022 (vs. 2020) (Hazard ratio [HR] 2.86; 95% CI 1.45–5.68) or those with isolated deep vein thrombosis (vs. pulmonary embolism) (HR 2.31; 95% CI 1.19–4.49) had significantly higher rates of VTE recurrences. Interpretation: In patients with COVID-19-associated VTE who discontinued anticoagulation after at least 3 months of treatment, the incidence rate of recurrent VTE and the case-fatality rate was low. Therefore, it conceivable that long-term anticoagulation may not be required for many patients with COVID-19-associated VTE, although further research is needed to confirm these findings. Funding: Sanofi and Rovi, Sanofi Spain